May 17, 2013 08:21 EDT The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation.
Press Releases
Mar 12, 2013 08:57 EDT Olink launches Proseek Multiplex – a new generation of multiplexed protein biomarker immunoassays. Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously. With Proseek Multiplex, 92 proteins can be quantified in just one microliter sample without compromising data quality or performance.
Feb 12, 2013 08:44 EST Uppsala, Sweden, February 12, 2013 – Olink Bioscience today announced the appointment of Sigma® Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, as distributor of the Duolink® In Situ product line in nearly all geographies worldwide for the research market.
Nov 21, 2011 09:00 EST Olink Bioscience, a Sweden based biotechnology company focused on innovative protein detection technologies, has entered into a distribution agreement with Bethyl Laboratories, Inc. Together with Bethyl Olink Bioscience will continue to expand the distribution of the Duolink® product line in the US market.
Sep 14, 2011 09:32 EDT UPPSALA, Sweden, 14 September 2011 – Dr. Simon Fredriksson, Executive Vice President and Chief Scientific Officer of Olink AB (Olink) has today been promoted to President and CEO of Olink. Simon Fredriksson is taking over from Björn Ekström who has been managing the company since its inception in 2004. At the same time new members of the Board of Directors have been appointed.
Aug 29, 2011 08:20 EDT nxt2b (Nexttobe AB) an investment company owned by Bengt Ågerup, has today signed an agreement with a group of shareholders in Olink AB to purchase 49 % of the outstanding shares in the company. The intention is to accelerate the growth and value creation of the company by injecting knowledge, experience and financial strength to complement Olink’s unique product and technology position.
Jun 15, 2011 03:41 EDT Simon Fredriksson co-founder and CSO of Olink AB has today been promoted to executive Vice President. With the new appointment follow increased responsibilities for global business development and external research collaborations.
Apr 27, 2011 09:21 EDT Proseek™ is a user friendly open assay development reagent kit for the detection and quantification of proteins in serum or plasma samples. It offers the same level of performance as ELISA, but uses extremely low sample volumes; only1 µl is required for each reaction thus enabling the scientist to study precious bio-banked materials and plasma from small laboratory animals.
Mar 24, 2011 04:00 EDT Olink Bioscience has signed a distributorship agreement with Sapphire Bioscience for the distribution of the Duolink® product line in Australia and New Zealand.
Mar 08, 2011 07:30 EST Olink Bioscience now offers a new research service, Plasma Biomarker Discovery Service. Using the multiplexed PLA® immunoassay platform, up to 74 potential cancer biomarkers are analyzed with high sensitivity in precious biobanked plasma samples, in no more than 2 µl of sample. This enables identification of novel biomarkers and contributies to the understanding of human cancer.
